Table 2 P53, BCL-2 and Cyclin D1 expression in GISTs related to clinicopathological features
Tumor size (cm) | Mitotic rate/50 HPF | Malignancy risk F | Malignancy risk M | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
<2 | 2–5 | 5–10 | >10 | <5 | 5–10 | >10 | very low | low | intermediate | high | prob benign | low | prob malign | |
P53 | 2/10 | 7/31 | 22/37 | 9/22 | 13/50 | 7/15 | 20/35 | 1/10 | 3/25 | 10/18 | 26/47 | 3/24 | 5/17 | 32/59 |
20% | 23% | 37% | 41% | 26% | 47% | 57% | 10% | 12% | 56% | 55% | 13% | 29% | 54% | |
BCL2 | 5/9 | 22/30 | 30/37 | 15/22 | 34/48 | 9/15 | 29/35 | 4/8 | 18/25 | 15/18 | 35/47 | 13/22 | 14/17 | 45/59 |
56% | 73% | 81% | 68% | 71% | 60% | 83% | 50% | 72% | 83% | 74% | 59% | 82% | 76% | |
CyD1 | 3/7 | 12/26 | 15/29 | 4/18 | 19/40 | 5/12 | 10/28 | 2/5 | 10/21 | 8/16 | 14/38 | 6/18 | 8/15 | 20/47 |
43% | 46% | 52% | 22% | 48% | 42% | 36% | 40% | 47% | 50% | 37% | 33% | 53% | 42% | |
Nuclear atypia | Proliferative activity | Histological subtype | Tumor site | |||||||||||
absent | mild | severe | <7% | ≥ 7% | spindle cell | epithelioid | stomach | small intestine | large intestine | |||||
P53 | 6/26 | 13/37 | 21/37 | 14/60 | 22/40 | 18/63 | 22/37 | 19/58 | 16/35 | 5/7 | ||||
23% | 35% | 56% | 23% | 55% | 29% | 59% | 33% | 46% | 71% | |||||
BCL2 | 18/25 | 25/36 | 29/37 | 9/26 | 27/72 | 43/61 | 29/37 | 37/56 | 30/35 | 5/7 | ||||
72% | 69% | 78% | 35% | 38% | 70% | 78% | 66% | 86% | 71% | |||||
CyD1 | 9/18 | 9/28 | 16/34 | 21/46 | 12/34 | 21/48 | 13/32 | 17/45 | 15/30 | 2/5 | ||||
50% | 32% | 47% | 46% | 35% | 44% | 41% | 38% | 50% | 40% | |||||